SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SSgA Active Trust - SPDR S&P 500 ETF Trust

The SPDR S&P 500 ETF Trust is trending as President Trump's threats of new tariffs on European nations over Greenland escalate geopolitical tensions, leading to a risk-off market sentiment. The community is divided, with some anticipating a significant market pullback, while others view it as a 'buy the dip' opportunity, also noting a Japan-led bond sell-off as a contributing factor. This environment is fueling discussions about broader market volatility and a flight to safe-haven assets.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is trending following constructive discussions with the FDA regarding a resubmission path for ANKTIVA in bladder cancer, complemented by significant international approvals and strategic partnerships like those recently established in Saudi Arabia for broader cancer indications. This development, coupled with high short interest, is fueling widespread community excitement about a potential paradigm shift in oncology and intense speculation regarding a short squeeze amidst growing calls for expedited access to these innovative treatments.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ is actively trending amid escalating US-EU trade tensions driven by President Trump's tariff threats over Greenland, sparking a widespread market sell-off and global risk-off sentiment. The investment community is sharply divided between those anticipating a deeper correction for technology and growth stocks and fervent "buy the dip" proponents. Immediate market focus remains on an upcoming Supreme Court ruling regarding tariff authority and a heavy week of earnings reports, amplifying uncertainty.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavax is a major talking point following its J.P. Morgan conference appearance, where investors are eagerly seeking clarity on its strategy for advancing the Matrix-M adjuvant technology and securing new collaborations. Community sentiment is sharply focused on management's pace in realizing pipeline potential, including a recent Pfizer agreement and ongoing Sanofi ventures, with an activist investor's growing stake and significant short interest adding to the intense market watch.

Corvus Pharmaceuticals, Inc. engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in South San Francisco, CA.

Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals is trending after announcing positive data from its placebo-controlled Phase 1 clinical trial of soquelitinib for atopic dermatitis, showing strong efficacy. The community is actively discussing the oral ITK inhibitor's potential in a large market, with many anticipating significant revaluation and partnership opportunities for its novel mechanism of action.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is gaining significant attention as its patented Optical Interposer platform is seen as crucial for next-generation AI and data center infrastructure, enabling highly efficient and scalable optical interconnects. The community is actively discussing recent product innovation awards and confirmed partnerships, including with Celestial AI (now Marvell), which validate its technology. Anticipation is also building for the imminent disclosure of major institutional investors, signaling strong long-term confidence.

BlackRock Institutional Trust Company N.A. - iShares 20+ Year Treasury Bond ETF

iShares 20+ Year Treasury Bond ETF

TLT is trending amid intense debate surrounding the Federal Reserve's independence, fueled by a federal probe into its Chair and the administration's aggressive policy maneuvers impacting bond markets. Investors are actively discussing whether long-term treasuries offer a crucial hedge against a potential economic slowdown or face further headwinds from escalating national debt and geopolitical uncertainty.

Ardelyx, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing biopharmaceutical products. The firm is also involved in developing a unique and innovative platform that enables the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet in October 2007 and is headquartered in Waltham, MA.

Ardelyx Inc

Ardelyx is trending as investors react to a significant patent extension for its key products until 2041, coupled with a bullish preliminary business update accelerating IBSRELA's path to $1 billion in revenue by 2029 and multiple analyst price target upgrades. The community is buzzing with renewed acquisition speculation and optimism over the company's long-term value, despite ongoing discussions about short-term price fluctuations attributed to market dynamics. This confluence of positive developments has many viewing Ardelyx as a significantly undervalued biotech with strong commercial execution.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

Applovin (APP) is actively trending amid recent allegations of money laundering and illicit financial ties, triggering a sharp sell-off across the stock. Despite this, community sentiment is divided, with many dismissing the claims as a coordinated short attack ahead of strong earnings, while others are seizing the opportunity to buy into the fundamentally strong AI-powered ad platform.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group Corp. (DJT) is seeing heightened conversation due to recent developments surrounding Trump's assertive stance on Greenland and reactions to a perceived Nobel Peace Prize snub, which has sparked discussions of new tariffs on European nations. The community is actively debating the potential for increased market volatility, geopolitical instability, and the broader economic ramifications of these actions. This ongoing dialogue underscores intense political polarization and its influence on market sentiment.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Zura Bio Reports Business Updates and Outlook for 2026

Zura Bio Limited (Nasdaq: ZURA) (Zura), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and...

Zura Bio Limited (NASDAQ:ZURA) Given Average Rating of "Moderate Buy" by Brokerages

Shares of Zura Bio Limited (NASDAQ:ZURA - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the six brokerages that are currently covering the stock, MarketBeat...

Zura Bio (NASDAQ:ZURA) Stock Price Down 1.5% - Here's What Happened

Zura Bio (NASDAQ:ZURA) Stock Price Down 1.5% - Here's Why...

Alberta Investment Management Corp Buys Shares of 133,200 Zura Bio Limited $ZURA

Alberta Investment Management Corp bought a new position in Zura Bio Limited (NASDAQ:ZURA - Free Report) during the 2nd quarter, according to its most recent disclosure with the Securities and...

Chardan Capital Reiterates Buy Rating for Zura Bio (NASDAQ:ZURA)

Chardan Capital reissued a "buy" rating and issued a $10.00 price target on shares of Zura Bio in a report on Friday...

Zura Bio Limited (NASDAQ:ZURA - Get Free Report) has been given an average rating of "Moderate Buy" by the six ratings firms that are presently covering the stock, Marketbeat.com reports. One analyst...

Wall Street Zen Downgrades Zura Bio (NASDAQ:ZURA) to Sell

Wall Street Zen lowered shares of Zura Bio from a "hold" rating to a "sell" rating in a research report on Sunday...

Zura Bio (NASDAQ:ZURA) Issues Earnings Results

Zura Bio (NASDAQ:ZURA - Get Free Report) released its quarterly earnings results on Thursday. The company reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.19) by ($0.02...

Zura Bio Reports Third Quarter 2025 Financial Results and Recent Corporate Updates

Zura Bio Limited (Nasdaq: ZURA) (Zura Bio or the Company), a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today...

Zura Bio (NASDAQ:ZURA) Rating Increased to Hold at Wall Street Zen

Wall Street Zen upgraded shares of Zura Bio from a "sell" rating to a "hold" rating in a research report on Saturday...

Zura Bio Ltd. is a clinical-stage biotechnology company, which engages in the development of novel medicines for immune disorders. It focuses on the development of ZB-168, a treatment for Alopecia Areata and other inflammatory diseases. The company was founded by Someit Sidhu on January 18, 2022 and is headquartered in Henderson, NV.

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	-$0.20	--	--	N/A
Q3 '25	-$0.19	-$0.21	-9.80%	MISSED
Q2 '25	-$0.19	-$0.17	9.73%	BEAT
Q1 '25	-$0.16	-$0.19	-19.82%	MISSED
Q4 '24	-$0.16	-$0.15	6.25%	BEAT

ZURA
Zura Bio Ltd - Ordinary Shares - Class A

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q4 '25

Historical Earnings

Latest ZURA News

ZURAZura Bio Ltd - Ordinary Shares - Class A